Phorbol ester-induced down-regulation of topoisomerase IIα mRNA in a human erythroleukemia cell line. Evidence for a post-transcriptional mechanism

Biochemical Pharmacology

Volumn 52, Issue 7, 1996, Pages 1065-1072

  Loflin, Paul T ^a,c   Altschuler, Elizabeth ^a   Hochhauser, Daniel ^b   Hickson, Ian D ^b   Zwelling, Leonard A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

differentiation; K562; mRNA; phorbol ester; post transcriptional regulation; topoisomerase II

Indexed keywords

COMPLEMENTARY DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2ALPHA; GAMMA GLOBIN; GENE PRODUCT; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PLATELET DERIVED GROWTH FACTOR B; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN K 562; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ERYTHROLEUKEMIA CELL; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEGAKARYOCYTE; NORTHERN BLOTTING; ONCOGENE C MYC; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0030580067     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00446-7     Document Type: Article

References (60)

1. 1. DiNardo S, Voelkel K and Sternglanz R, DNA topoisomerase II mutant of Saccharomyces cerevisiae: Topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 81: 2616-2620, 1984.
2. 2. Nelson WG, Liu LF and Coffey DS, Newly replicated DNA is associated with DNA topoisomerase II in cultured prostatic adenocarcinoma cells. Nature 322: 187-192, 1986.
3. 3. Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS and Whang-Peng J, Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res 48: 512-516, 1988.
4. 4. Bae YS, Kawaski I, Ikeda H and Liu LF, Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vivo. Proc Natl Acad Sci USA 85: 2067-2080, 1988.
5. 5. Holm C, Goto T, Wang JC and Botstein D, DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553-558, 1985.
6. 6. Uemura T and Yanagida M, Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: Uncoordinated mitosis. EMBO J 5: 1003-1010, 1986.
7. 7. Osheroff N, Zechiedrich EL and Gale KC, Catalytic function of DNA topoisomerase II. Bioessays 13: 269-274, 1991.
8. 8. Rovera G, O'Brien TG and Diamond L, Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204: 868-870, 1991.
9. 9. Huberman E and Callahan MF, Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 76: 1293-1297, 1979.
10. 10. Leftwich JA, Carlson P, Adelman B and Hall RE, HL-60-1E3, a novel phorbol diester-resistant HL-60 cell line. Cancer Res 47: 1319-1324, 1987.
11. 11. Macfarlane DE, Gailani JD and Vann K, A phorbol ester tolerant (PET) variant of HL-60 promyelocytes. Br J Haematol 68: 291-302, 1988.
12. 12. Zwelling LA, Hinds M, Chan D, Altschuler E, Mayes J and Zipf TF, Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation. Cancer Res 50: 7116-7122, 1990.
13. 13. Ellis AL, Altschuler E, Bales E, Hinds M, Mayes J, Soares L, Zipf TF and Zwelling LA, Phorbol regulation of topoisomerases I and II in human leukemia cells. Studies in an additional cell pair sensitive or resistant to phorbol-induced differentiation. Biochem Pharmacol 47: 387-396, 1994.
14. 14. Ellis AL and Zwelling LA, Time course of phorbol-12-myristate-13-acetate (PMA) induced down-regulation of topoisomerase II in human leukemia cells. Biochem Pharmacol 48: 1842-1845, 1994.
15. 15. Loflin PT and Zwelling LA, Topoisomerase II and the path to apotosis. Contemp Oncol 4: 42-57, 1994.
16. 16. Bugg BY, Danks MK, Beck WT and Suttle DP, Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acal Sci USA 88: 7634-7638, 1991.
17. 17. Hinds M, Deisseroth K, Mayes J Altschuler E, Jansen R, Ledley FD and Zwelling LA, Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amascrine-resistant form of topoisomerase II. Cancer Res 51: 4729-4731, 1991.
18. 18. Lee MS, Wang JC and Beran M, Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223: 837-843, 1992.
19. 19. Chan VTW, Ng SW, Eder JP and Schnipper LE, Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from a etoposide-resistant Chinese hamster ovary cell line. J Biol Chem 268: 2160-2165, 1993.
20. γ 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53: 1373-1379, 1993.
21. 21. Jannatipour M, Liu Y-X and Nitiss JL, The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J Biol Chem 268: 18586-18592, 1993.
22. 22. Kubo A, Nakagawa K, Fukuoka M, Yoshikawa A, Hirashima K, Tamura T, Yana T, Masuda N, Matsui K, Kusunoki Y, Kawase I and Takada M, Identification of a point mutation in the α-topoisomerase II cDNA from human small cell lung cancer treated previously with etoposide. Proc Am Assoc Cancer Res 36: 447, 1995.
23. 23. Godenberg GJ, Wang H and Blair GW, Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single-and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 46: 2978-2981, 1986.
24. 24. Deffie AM, Batra JK and Godenberg GJ, Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
25. 25. Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS and Cheng YC, Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956-5964, 1988.
26. 26. de Jong S, Kooistra AJ, de Vries EGE, Mulder NH and Zijlstra JG, Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res 53: 1064-1071, 1993.
27. 27. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID, Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991.
28. 28. Tetteroo PAT, Massaro F, Mulder A, Schreuder-van Gelder R and von dem Borne AEGKr, Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells. Leuk Res 8: 197-206, 1984.
29. 29. Chomczynski P and Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
30. 30. Sambrook J, Fristch EF and Maniatis T, Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.
31. 31. Hochhauser D, Stanway CA, Harris AL and Hickson ID, Cloning and characterization of the 5′ flanking region of the human topoisomerase IIα gene. J Biol Chem 267: 18961-18965, 1992.
32. 32. Groudine M, Peretz M and Weintraub H, Transcriptional regulation of hemoglobin switching in chicken embryos. Mol Cell Biol 1: 281-288, 1981.
33. 33. McKnight GS and Palmiter RD, Transcriptional regulation of the ovalbumin and conalbumin genes by steroid hormones in chick oviduct. J Biol Chem 254: 9050-9058, 1979.
34. 34. Sagoh T and Yamada M, Transcriptional regulation of myeloperoxidase gene expression in myeloid leukemia HL-60 cells during differentiation into granulocytes and macrophages. Arch Biochem Biophys 262: 599-604, 1988.
35. 35. Lumelsky NL and Forget BG, Negative regulation of globin gene expression during megakaryocytic differentiation of a human erythroleukemic cell line. Mol Cell Biol 11: 3528-3536, 1991.
36. 36. Mäkelä TP, Alitalo R, Paulsson Y, Westermark B, Heldin CH and Alitalo K, Regulation of platelet-derived growth factor gene expression by transforming growth factor β and phorbol esters in human leukemia cell lines. Mol Cell Biol 7: 3656-3662, 1987.
37. 37. Gomez-Casares MT, Delgado MD, Lerga A, Crespo P, Quincoces AF, Richard C and Leon J, Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells. Leukemia 7: 1824-1833, 1993.
38. 38. Alitalo R, Induced differentiation of K562 leukemia cells: A model for studies of gene expression in early megakaryoblasts. Leuk Res 14: 501-514, 1990.
39. 39. Sandberg K, Eloranta M-L, Gobl AE and Alm GV, Phorbol ester-mediated inhibition of IFN-α/β gene transcription in blood mononuclear leukocytes. J Immunol 147: 3116-3121, 1991.
40. 40. Rabin MS, Doherty PJ and Gottesman MM, The tumor promoter phorbol 12-myristate 13-acetate induces a program of altered gene expression similar to that induced by platelet-derived growth factor and transforming oncogenes. Proc Natl Acad Sci USA 83: 357-368, 1986.
41. 41. Mitchell P, Wang C and Tjian R, Positive and negative regulation of transcription in vitro: Enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 50: 847-861, 1987.
42. 42. Maekawa T, Sakura H, Kanei-Ishii C, Sudo T, Yoshimura T, Fujisawa J-I, Yoshida M and Ishii S, Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J 8: 2023-2028, 1989.
43. 43. Rorth P, Nerlov C, Blasi F and Johnsen M, Transcriptional factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor of phorbol-ester. Nucleic Acids Res 18: 5009-5014, 1990.
44. 44. Loflin PT, Hochhauser D, Hickson ID, Morales F and Zwelling LA, Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase IIα gene promoter. Biochem Biophys Res Commun 200: 489-496, 1994.
45. 45. Bentley DL and Groudine M, A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 321: 702-706, 1986.
46. 46. Eick D and Bornkamm GW, Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression. Nucleic Acids Res 14: 8331-8346, 1986.
47. 47. Atwater JA, Wisdom R and Verma IM, Regulated mRNA stability. Annu Rev Genet 24: 519-541, 1990.
48. 48. Schuler GD and Cole MD, GM-CSF and oncogene mRNA stabilities are independently regulated in trans, in a mouse monocytic tumor. Cell 55: 1115-1122, 1988.
49. 49. Shaw G and Kamen R, A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659-667, 1986.
50. 50. Jones TR and Cole MD, Rapid cytoplasmic turnover of c-myc mRNA: Requirement of the 3′ untranslated sequences. Mol Cell Biol 7: 4513-4521, 1987.
51. 51. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M and Masaki T, The human preproendothelin-1 gene. J Biol Chem 264: 14954-14959, 1989.
52. 52. Antalis M and Dickinson JL, Control of Plaminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells. Eur J Biochem 205: 203-209, 1992.
53. 53. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Wang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC, Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to the chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177-7181, 1988.
54. 54. Pandey NB and Marzluff WF, The stem loop structure at the 3′ end of histone mRNA is necessary and sufficient for regulation of histone mRNA stability. Mol Cell Biol 7: 4557-4559, 1987.
55. 55. Müllner EW and Kühn LC, A stem-loop in the 3′ untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm. Cell 36: 51-60 1988.
56. 56. Koeller DM, Casey JL, Hentze MW, Gerhardt EM, Chan LNL, Klausner RD and Harford JB, A cytosolic protein binds to structural elements within the iron regulatory region of the transferrin receptor mRNA. Proc Natl Acad Sci USA 86: 3574-3578, 1989.
57. 57. Narayanan DS, Fujimoto J, Geras-Raaka E and Gershengorn MC, Regulation by thyrotropin-releasing hormone (TRH) of TRH receptor mRNA degradation in rat pituitary GH3 cells. J Biol Chem 267: 17296-17303, 1992.
58. 58. Lee NH, Earle-Hughes J and Fraser CM, Agonist-mediated destabilization of M1 muscarinic acetylcholine receptor mRNA. J Biol Chem 269: 4291-4298, 1994.
59. 59. Treisman R, Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5′ element and c-fos 3′ sequences. Cell 42: 889-902, 1985.
60. 60. Rahmsdorf HJ, Schönthal A, Angel P, Litfin M, Rüther U and Herrlich P, Posttranscriptional regulation of c-fos mRNA expression. Nucleic Adds Res 15: 1643-1659, 1987.